This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

This study has suspended participant recruitment.
(Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.)
Information provided by:
AstraZeneca Identifier:
First received: July 15, 2009
Last updated: January 21, 2011
Last verified: January 2011
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose

Condition Intervention Phase
Absorption Distribution Metabolism Excretion Drug: AZD7325 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To assess absorption, distribution, metabolism and excretion of AZD7325 after IV dose and 14C oral dose administration [ Time Frame: Daily ]

Secondary Outcome Measures:
  • To evaluate safety and tolerability after a single oral administration of [14C] AZD7325 and after a single intravenous administration of non radio-labelled AZD7325 [ Time Frame: Daily ]

Estimated Enrollment: 8
Study Start Date: August 2009
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
IV dose of AZD7325
Drug: AZD7325
IV Dose
Experimental: 2
14C oral dose of AZD7325
Drug: AZD7325
oral dose


Ages Eligible for Study:   35 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects Day 1
  • Body Mass Index (BMI) > 18 and < 30kg/m2

Exclusion Criteria:

  • Clinically relevant disease and abnormalities (past or present) which in the opinion of the investigator, may either put the subject at risk to participate in this study or may influence the results of the study or the subject's ability to participate in the study
  • Use of prescription medication within 14 days of the first dose of the investigational product
  • Blood loss in excess of 200 mL within 30 days of Day-1 in excess of 500 mL within 90 days of Day-1 or in excess of 1350 mL within 1 year of Day-1 or donation of blood products within 14 days of Day -1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00940641

United Kingdom
Research Site
Alderley Park, United Kingdom
Sponsors and Collaborators
Principal Investigator: Raj Chetty, MBBS, MD, FRCPath. AstraZeneca Alderly Park CPU
  More Information

Responsible Party: Raj Tummala, M.D./MSD, AstraZeneca Identifier: NCT00940641     History of Changes
Other Study ID Numbers: D1140C00017
Study First Received: July 15, 2009
Last Updated: January 21, 2011

Keywords provided by AstraZeneca:
Healthy Volunteer processed this record on August 22, 2017